Clay Siegall is a revered biotechnology professional who is appreciated for the discoveries that he has made in cancer research. He has been a top a science researcher for the past three decades and currently serves Seattle Genetics, which is an institution that he established. Siegall is the chairperson of the company and has led it in offering excellent cancer therapies to the world. He started Seattle Genetics as a typical biotech research enterprise and has currently transformed it into a research hub that works with several scientists. Chemotherapies that are currently being used as cancer cures cause a lot of damage to the human body. The drugs that have been developed by Seattle Genetics are not harmful, and they are highly effective. The company has strived to advance its therapies over the years and is now working to create drugs that are customized for specific individuals.
Seattle Genetics started off as a small enterprise and had its IPO in 2001. The company has been organizing private and public funding programs, and it has so far received more the $675 million from investors. Some of the drugs that the firm has developed have been certified by the FDA, and they are currently being sold in the local and international markets. Seattle Genetics makes profits that enable it to sustain its operations.
The biotechnology company has had a significant impact on the pharmaceuticals sector, and this has made Clay Siegall famous. Before launching the company, he served as a researcher at Bristol-Myers Squibb, which is a leading pharmaceutical research institute. He was also hired to conduct biotechnology and genetics studies at the National Cancer Institute.
Clay Siegall has worked with Seattle Genetics’ scientists in developing a targeted cancer treatment that is called the antibody-drug conjugates technology (ADCs). This has been the greatest accomplishment of the company. The first FDA approval that the firm received was in 2011, and it was for a drug that is called ADCETRIS. Seattle Genetics currently has 20 certified ADCs that have been commercialized both in the United States and abroad. The company is determined to conduct more research in cancer treatment to develop a permanent cure for the problem.